Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Systematic screening identifies dual PI3K and mTOR Inhibition as a conserved therapeutic vulnerability in osteosarcoma
Author: Gupte, A.
Baker, E.
Wan, S.
Stewart, E.
Loh, A.
Shelat, A.
Gould, C.
Chalk, A.
Taylor, S.
Lackovic, K.
Karlström, Å.
Mutsaers, A.
Desai, J.
Madhamshettiwar, P.
Zannettino, A.
Burns, C.
Huang, D.
Dyer, M.
Simpson, K.
Walkley, C.
Citation: Clinical Cancer Research, 2015; 21(14):3216-3229
Publisher: American Association for Cancer Research
Issue Date: 2015
ISSN: 1557-3265
Statement of
Ankita Gupte, Emma K. Baker, Soo-San Wan, Elizabeth Stewart, Amos Loh, Anang A. Shelat, Cathryn M. Gould, Alistair M. Chalk, Scott Taylor, Kurt Lackovic, Åsa Karlstr, om, Anthony J. Mutsaers, Jayesh Desai, Piyush B. Madhamshettiwar, Andrew C.W. Zannettino, Chris Burns, David C.S. Huang, Michael A. Dyer, Kaylene J. Simpson, and Carl R.Walkley
Abstract: Abstract not available
Keywords: Animals; Humans; Mice; Osteosarcoma; Bone Neoplasms; Disease Models, Animal; RNA, Small Interfering; Antineoplastic Agents; Drug Screening Assays, Antitumor; Xenograft Model Antitumor Assays; Genetic Engineering; Cell Proliferation; Phosphatidylinositol 3-Kinases; TOR Serine-Threonine Kinases; High-Throughput Nucleotide Sequencing
Description: Disclosure of Potential Conflicts of Interest J. Desai is a consultant/advisory board member for GlaxoSmithKline, Novartis, and Roche. No potential conflicts of interest were disclosed by the other authors.
Rights: ©2015 American Association for Cancer Research.
RMID: 0030027597
DOI: 10.1158/1078-0432.ccr-14-3026
Grant ID:
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.